FDA Approves Unknown Drug — ZHEJIANG NOVUS
Zhejiang Novus announced the receipt of FDA approval for its ANDA, a strategic milestone expected to bolster the company’s commercial portfolio and drive significant revenue growth upon launch.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day